Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Releases Earnings Results, Beats Expectations By $0.17 EPS

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) announced its earnings results on Wednesday. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.17, FiscalAI reports. The business had revenue of $2.51 million during the quarter, compared to the consensus estimate of $0.40 million. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.57%.

Armata Pharmaceuticals Trading Up 11.8%

NYSEAMERICAN ARMP opened at $4.82 on Friday. The company has a market cap of $176.94 million, a price-to-earnings ratio of -0.63 and a beta of 1.30. The company has a 50 day moving average of $5.64 and a 200-day moving average of $8.13. Armata Pharmaceuticals has a 1-year low of $2.39 and a 1-year high of $16.34.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded Armata Pharmaceuticals to a “hold” rating in a research note on Monday, May 18th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Armata Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $15.00.

Institutional Trading of Armata Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in Armata Pharmaceuticals by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 109,888 shares of the company’s stock valued at $690,000 after purchasing an additional 5,342 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new position in Armata Pharmaceuticals in the 4th quarter valued at about $177,000. State Street Corp raised its position in shares of Armata Pharmaceuticals by 26.1% in the 4th quarter. State Street Corp now owns 50,800 shares of the company’s stock valued at $319,000 after buying an additional 10,500 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Armata Pharmaceuticals by 65.9% in the 4th quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock valued at $430,000 after buying an additional 27,200 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Armata Pharmaceuticals during the 4th quarter worth approximately $284,000. 3.57% of the stock is currently owned by institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.